Assessment of serum hepcidin levels in patients with non-ST elevationmyocardial infarction

Basit Öğe Kaydı
dc.contributor.authorAltun, Burak
dc.contributor.authorAltun, Mehzat
dc.contributor.authorAcar, Gürkan
dc.contributor.authorKılınç, Metin
dc.contributor.authorTaşolar, Mehmet Hakan
dc.contributor.authorKüçük, Ahmet
dc.contributor.authorTemiz, Ahmet
dc.date.accessioned2025-01-27T19:41:36Z
dc.date.available2025-01-27T19:41:36Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: Hepcidin is an acute-phase reactant produced in the liver displaying intrinsic antimicrobial activity. There are few studies abouthepcidin considered to be acute and chronic inflammatory marker in acute coronary syndromes patients. We investigated in our study wheth-er the level of hepcidin has increased in the acute phase of non-ST elevation myocardial infarction patients (NSTEMI) known as acute inflam-matory aggravation of chronic atherosclerotic process.Methods: Seventy patients with NSTEMI and twenty healthy people were recruited as controls in this observational cross-sectional study.Serum hepcidin levels were determined by ELISA, and troponin levels were measured by standard laboratory methods. Levels of hepcidin andtroponin were measured at admission and 6 hours later. Mean values of continuous variables were compared between groups using theStudent t-test or Mann-Whitney U test, according to whether normally distributed or not, as tested by the Kolmogorov-Smirnov test. Serumtroponin and hepcidin levels measured at admission and after 6th hours were compared using paired t-test.Results: Hepcidin level was similar between NSTEMI and controls at admission (24.55±32.13, 23.67±33.62 ng/mL, p>0.05, respectively). Also, serum hepcidinlevels did not change significantly from baseline in blood samples taken after 6 hour from admission in NSTEMI patients (24.55±32.13 ng/mL, 29.75±31.48ng/mL, p=0.62, respectively). However, serum troponin levels were increased significantly compared to baseline (0.29±3.56, 2.92±7.2 ng/mL, p<0.01).Conclusion: Our findings suggest that hepcidin could not be use as a marker of myocardial necrosis in acute phase such as troponin in patientswith NSTEMI.
dc.identifier.endpage518
dc.identifier.issn1302-8723
dc.identifier.issn1308-0032
dc.identifier.issue6
dc.identifier.startpage515
dc.identifier.trdizinid170690
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/170690
dc.identifier.urihttps://hdl.handle.net/20.500.12428/17746
dc.identifier.volume14
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofAnadolu Kardiyoloji Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TRD_20250125
dc.subjectTıbbi Araştırmalar Deneysel
dc.subjectKalp ve Kalp Damar Sistemi
dc.titleAssessment of serum hepcidin levels in patients with non-ST elevationmyocardial infarction
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu